Cumberland Pharmaceuticals Statistics
Share Statistics
Cumberland Pharmaceuticals has 14.04M shares outstanding. The number of shares has increased by -0.95% in one year.
| Shares Outstanding | 14.04M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.38% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 7.84M |
| Failed to Deliver (FTD) Shares | 14.21K |
| FTD / Avg. Volume | 0.76% |
Short Selling Information
The latest short interest is 1.47M, so 10.46% of the outstanding shares have been sold short.
| Short Interest | 1.47M |
| Short % of Shares Out | 10.46% |
| Short % of Float | 18.7% |
| Short Ratio (days to cover) | 0.29 |
Valuation Ratios
The PE ratio is -4.08 and the forward PE ratio is 8.57.
| PE Ratio | -4.08 |
| Forward PE | 8.57 |
| PS Ratio | 0.65 |
| Forward PS | null |
| PB Ratio | 0.86 |
| P/FCF Ratio | 4.54 |
| PEG Ratio | n/a |
Enterprise Valuation
Cumberland Pharmaceuticals Inc. has an Enterprise Value (EV) of 25.70M.
| EV / Earnings | -4.09 |
| EV / Sales | 0.65 |
| EV / EBITDA | 167.64 |
| EV / EBIT | -4.14 |
| EV / FCF | 4.56 |
Financial Position
The company has a current ratio of 1.28, with a Debt / Equity ratio of 0.62.
| Current Ratio | 1.28 |
| Quick Ratio | 1.11 |
| Debt / Equity | 0.62 |
| Total Debt / Capitalization | 38.37 |
| Cash Flow / Debt | 0.33 |
| Interest Coverage | -9.3 |
Financial Efficiency
Return on equity (ROE) is -0.21% and return on capital (ROIC) is -13.12%.
| Return on Equity (ROE) | -0.21% |
| Return on Assets (ROA) | -0.08% |
| Return on Capital (ROIC) | -13.12% |
| Revenue Per Employee | 434.64K |
| Profits Per Employee | -69.00K |
| Employee Count | 91 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 1.32 |
Taxes
| Income Tax | 45.77K |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by 38.97% in the last 52 weeks. The beta is 0.22, so Cumberland Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.22 |
| 52-Week Price Change | 38.97% |
| 50-Day Moving Average | 1.71 |
| 200-Day Moving Average | 1.51 |
| Relative Strength Index (RSI) | 67.72 |
| Average Volume (20 Days) | 1.88M |
Income Statement
In the last 12 months, Cumberland Pharmaceuticals had revenue of 39.55M and earned -6.28M in profits. Earnings per share was -0.44.
| Revenue | 39.55M |
| Gross Profit | 33.49M |
| Operating Income | -6.21M |
| Net Income | -6.28M |
| EBITDA | 153.32K |
| EBIT | -6.21M |
| Earnings Per Share (EPS) | -0.44 |
Balance Sheet
The company has 18.32M in cash and 18.43M in debt, giving a net cash position of -106.86K.
| Cash & Cash Equivalents | 18.32M |
| Total Debt | 18.43M |
| Net Cash | -106.86K |
| Retained Earnings | -17.49M |
| Total Assets | 76.75M |
| Working Capital | 4.15M |
Cash Flow
In the last 12 months, operating cash flow was 6.09M and capital expenditures -453.05K, giving a free cash flow of 5.64M.
| Operating Cash Flow | 6.09M |
| Capital Expenditures | -453.05K |
| Free Cash Flow | 5.64M |
| FCF Per Share | 0.39 |
Margins
Gross margin is 84.66%, with operating and profit margins of -15.7% and -15.88%.
| Gross Margin | 84.66% |
| Operating Margin | -15.7% |
| Pretax Margin | -15.89% |
| Profit Margin | -15.88% |
| EBITDA Margin | 0.39% |
| EBIT Margin | -15.7% |
| FCF Margin | 14.26% |
Dividends & Yields
CPIX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -16.24% |
| FCF Yield | 14.82% |
Analyst Forecast
Currently there are no analyst rating for CPIX.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 0.07 |
| Piotroski F-Score | 5 |